Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2012 | 1 |
2013 | 3 |
2014 | 2 |
2024 | 0 |
Search Results
5 results
Results by year
Filters applied: . Clear all
It looks like you are searching for an author.
Results are currently sorted by Best Match. To see the newest results first,
change the sort order to Most Recent.
Page 1
Lipid levels and changes in body fat distribution in treatment-naive, HIV-1-Infected adults treated with rilpivirine or Efavirenz for 96 weeks in the ECHO and THRIVE trials.
Clin Infect Dis. 2014 Aug 1;59(3):425-34. doi: 10.1093/cid/ciu234. Epub 2014 Apr 11.
Clin Infect Dis. 2014.
PMID: 24729492
Clinical Trial.
Week 96 analysis of rilpivirine or efavirenz in HIV-1-infected patients with baseline viral load ≤ 100 000 copies/mL in the pooled ECHO and THRIVE phase 3, randomized, double-blind trials.
Molina JM, Clumeck N, Orkin C, Rimsky LT, Vanveggel S, Stevens M; ECHO and THRIVE Study Groups.
Molina JM, et al.
HIV Med. 2014 Jan;15(1):57-62. doi: 10.1111/hiv.12071. Epub 2013 Aug 28.
HIV Med. 2014.
PMID: 23980523
Free article.
Clinical Trial.
Item in Clipboard
Efficacy and safety of rilpivirine in treatment-naive, HIV-1-infected patients with hepatitis B virus/hepatitis C virus coinfection enrolled in the Phase III randomized, double-blind ECHO and THRIVE trials.
Nelson M, Amaya G, Clumeck N, Arns da Cunha C, Jayaweera D, Junod P, Li T, Tebas P, Stevens M, Buelens A, Vanveggel S, Boven K; ECHO and THRIVE Study Groups.
Nelson M, et al.
J Antimicrob Chemother. 2012 Aug;67(8):2020-8. doi: 10.1093/jac/dks130. Epub 2012 Apr 24.
J Antimicrob Chemother. 2012.
PMID: 22532465
Free PMC article.
Clinical Trial.
Item in Clipboard
Neurological and psychiatric tolerability of rilpivirine (TMC278) vs. efavirenz in treatment-naïve, HIV-1-infected patients at 48 weeks.
Mills AM, Antinori A, Clotet B, Fourie J, Herrera G, Hicks C, Madruga JV, Vanveggel S, Stevens M, Boven K; ECHO and THRIVE study groups.
Mills AM, et al.
HIV Med. 2013 Aug;14(7):391-400. doi: 10.1111/hiv.12012. Epub 2013 Jan 9.
HIV Med. 2013.
PMID: 23298380
Free article.
Clinical Trial.
Item in Clipboard
Rilpivirine vs. efavirenz in HIV-1 patients with baseline viral load 100,000 copies/ml or less: week 48 phase III analysis.
Molina JM, Clumeck N, Redant K, Rimsky L, Vanveggel S, Stevens M; ECHO and THRIVE Study Groups.
Molina JM, et al.
AIDS. 2013 Mar 27;27(6):889-897. doi: 10.1097/QAD.0b013e32835e1554.
AIDS. 2013.
PMID: 23276806
Clinical Trial.
Item in Clipboard
Cite
Cite